Source comparison
The Unvarnished Truth About Branded vs Research-Grade Peptides
Here's the honest answer: Egrifta is not a better version of tesamorelin. It's the same peptide sold at a 10–15× markup because it carries FDA approval for a specific therapeutic use. The regulatory pathway Theratechnologies completed to bring Egrifta to marke
This comparison does not assign a generated winner or score.
- Here's the honest answer: Egrifta is not a better version of tesamorelin. It's the same peptide sold at a 10–15× markup because it carries FDA approval for a specific therapeutic use. The regulatory pathway Theratechnologies completed to bring Egrifta to market cost tens of millions of dollars and took years of clinical trials, which justified the pricing. But the molecule synthesised by Real Peptides for research purposes contains the exact same 44-amino-acid sequence, purified to the same >98% threshold, and verified by the same analytical methods (HPLC, mass spectrometry).
- The branding creates a perception of exclusivity that doesn't exist at the molecular level. If you're conducting non-clinical research, paying for Egrifta is paying for regulatory compliance you don't need. If you're in a clinical setting treating HIV-associated lipodystrophy, Egrifta is the legally required option. The quality difference isn't in the peptide. It's in the oversight structure. Choose based on your compliance requirements, not on assumptions that FDA approval changes the chemistry.
- If the question is 'what's the difference between tesamorelin and Egrifta'. The answer is branding, not biology. Don't let pharmaceutical marketing convince you otherwise.